SCHEDULE: Annovis Bio Stakeholder Filing

Empery Asset Management, LP and Ryan M. Lane report a 5.64% stake in Annovis Bio, Inc. as of June 30, 2026.

Summary

• Empery Asset Management, LP, acting as the investment manager for certain funds, and Ryan M. Lane, the managing member of the general partner of the investment manager, have collectively reported beneficial ownership of 2,401,476 shares of Annovis Bio, Inc. common stock.
• This holding represents 5.64% of the company's outstanding common stock as of May 19, 2026.
• The filing is a Schedule 13G, indicating that the reporting persons are passive investors and do not intend to influence or change the control of the issuer.
• The reporting persons have disclaimed beneficial ownership of shares held by each other, except for their respective roles as investment manager and reporting individual.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports ownership stakes and does not contain operational updates or financial performance indicators that would suggest a significant shift in the company's valuation.

Positives

• Reporting persons hold a significant stake (5.64%) in Annovis Bio, Inc., indicating investor confidence.
• The filing is a Schedule 13G, suggesting a passive investment approach, which is generally viewed positively by the market as it implies a focus on the company's performance rather than activist intervention.

Negatives

• No specific financial performance data or company updates are provided in this filing, limiting the assessment of the company's current operational health.

Risks

• The filing does not detail specific risks related to Annovis Bio, Inc.'s operations or market position.
• Potential risks associated with passive investment stakes include the possibility of significant share sales impacting stock price if the reporting persons decide to divest.

Future Outlook

This filing is a Schedule 13G and does not contain forward-looking statements or specific guidance from the company regarding its future performance.

Management Comments

• Each of the Empery Funds and the Reporting Individual hereby disclaims any beneficial ownership of any such Common Stock (held by the other).
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors taking significant passive stakes in biotechnology companies, often as part of broader portfolio diversification or strategic investment strategies. The biotech sector is known for its volatility, making such disclosures important for understanding ownership structures.

Stakeholder Impact

• Shareholders: The passive nature of this investment suggests no immediate intent to influence corporate strategy, but a significant divestment could impact share price.
• Management: The filing confirms a substantial passive investor, which may influence future strategic decisions if the investor's interests align or diverge from management's.
• Creditors: No direct impact is indicated, as the filing pertains to equity ownership.

Next Steps

• Monitoring future filings from Empery Asset Management, LP and Ryan M. Lane for any changes in their stake in Annovis Bio, Inc.
• Observing Annovis Bio, Inc.'s operational and financial performance for insights into the company's strategic direction and potential impact on its stock.

Key Dates

Keywords

Annovis Bio, Schedule 13G, Empery Asset Management, Ryan M. Lane, Beneficial Ownership, Common Stock, Investment Manager, Passive Investor